The ability of rapamycin to inhibit mTORC1 signaling and subsequently reduce CCL2 production, cell migration, and dendritic cell maturation suggests its potential as a therapeutic agent for managing atherosclerosis. The gene discussed is CCL2; the disease is atherosclerosis.